Medically Reviewed by: Charles H. Weaver, MD
Over the past five years, CancerConnect’s online community has received thousands of questions from patients and caregivers trying to understand ctDNA and minimal or molecular residual disease (MRD) testing and what these results really mean for their care. ctDNA‑based MRD testing is increasingly used to help doctors detect tiny amounts of remaining cancer, estimate the risk of recurrence, and personalize decisions about treatment and follow‑up. This FAQ was created to answer the most common questions asked and to help you feel more informed and prepared when you talk with your care team about MRD testing.
What is ctDNA and MRD testing in lung cancer?
Minimal or molecular residual disease (MRD) is the term doctors use when a very small amount of lung cancer remains after treatment—too little to be seen on scans but still important to detect. Circulating tumor DNA (ctDNA) refers to tiny fragments of lung cancer DNA that are released into the bloodstream by the cancer cells. ctDNA‑based MRD testing is designed to detect these tiny traces of lung cancer DNA in blood, which is a sign that cancer is still present in the body and is likely to recur even if scans look normal.
How is MRD testing different from regular scans or blood tests?
Imaging tests (like chest CT, MRI, or PET scans) show cancer when the cancer is large enough to detect by imaging, MRD testing can sometimes find lung cancer DNA weeks, months, or even years before anything appears on scans. Standard blood tests may look at general markers (such as blood counts or organ function), but MRD tests are designed to detect DNA changes that are specific to lung cancer.
How does MRD testing work?
Most MRD tests used in lung cancer are “personalized” or “tumor‑informed,” meaning they start with a sample of your lung tumor (for example, from surgery or a biopsy) to identify its unique DNA changes. A custom blood test is then created, and future blood draws are checked for those same DNA changes to see if lung cancer DNA is still present in your bloodstream.
Who might benefit from MRD testing in lung cancer?
MRD testing is the most powerful prognostic indicator of cancer recurrence, MRD testing is best performed prior to surgery if you have non‑small cell lung cancer. Checking after surgery and systemic treatment can determine if you are responding to treatment or not and should consider more aggressive therapy. It may also be considered if your lung cancer has come back before or if you and your doctor want closer monitoring between scans, especially when your risk of recurrence is higher based on stage or tumor features.
What can MRD test results show?
MRD results generally fall into two main categories:
- MRD negative: No lung cancer DNA is detected in your blood above the test’s limit at that time, which can be a reassuring sign and is often linked to a lower risk of recurrence and improved prognosis.
- MRD positive: Lung cancer DNA is found in your blood, which typically means cancer is still present or starting to return, even if scans look normal.
Your doctor will interpret these results in the context of your lung cancer type (such as non‑small cell or small cell), stage, treatment history, and other test results.
How can MRD testing help guide lung cancer treatment decisions?
MRD results can help your care team:
- Determine your initial prognosis.
- Detect possible recurrence earlier and consider starting treatment sooner.
- Track how well chemotherapy, targeted therapy, immunotherapy, or other systemic treatments are working.
- Decide whether to continue, change, or stop certain therapies, especially if MRD stays positive or becomes negative on repeated tests.
In some situations, MRD testing may help avoid unnecessary or prolonged treatment if MRD is repeatedly negative, which may reduce side effects and improve quality of life, though these decisions are always individualized.
How often is MRD testing done in lung cancer?
MRD testing can be done on a regular schedule—such as every 2-3 months or at key time points after surgery, radiation, or chemoradiation—depending on your situation and your oncologist’s recommendations. The goal is to give you and your doctor a clearer, more continuous picture of your lung cancer status between scans.
Does a positive MRD result mean my lung cancer will definitely come back?
A positive MRD result suggests that lung cancer DNA is present and that there is a very high risk of recurrence. Your doctor may recommend closer monitoring, additional imaging, or changes to your treatment plan (for example, adding or changing systemic therapy) based on this result and your overall risk factors.
Does a negative MRD result mean I am “cancer‑free”?
A negative MRD result means the test did not detect lung cancer DNA above its limit of detection at that time. This is encouraging, but no test is perfect, so you will still be monitored .
Can ctDNA/MRD testing reduce how often I need scans?
Some research suggests that patients who remain ctDNA‑negative over time are at lower risk for recurrence, which could eventually support less frequent use of CT or MRI imaging for certain people in the future. For now, ctDNA/MRD testing is generally used alongside—not instead of—routine imaging, and any changes to your scan schedule should be decided together with your care team.
What is the difference between a “tumor-informed” MRD test and a blood-based ctDNA test?
A “tumor-informed” MRD test and a blood-based ctDNA test are both blood tests that look for evidence of cancer in the bloodstream, but they are designed and used a bit differently.
In a tumor-informed MRD test, the lab starts by analyzing a sample of your tumor tissue (for example, from surgery or a biopsy). They look for the specific DNA changes (mutations) that are unique to your cancer. Then they create a personalized blood test that checks your blood for those exact changes over time. Because it is tailored to your tumor, this type of test can be very sensitive for finding very low levels of remaining cancer after treatment and for monitoring whether cancer might be coming back.
With a more general blood-based MRD test (sometimes called “tumor-naive” or “tumor-agnostic”), the lab does not use your tumor tissue to create a personalized test. Instead, the test looks in your blood for a panel of common cancer-related changes to the DNA. This can be useful when tumor tissue is unavailable, but it is less sensitive and specific than a tumor-informed test.
In simple terms:
- Tumor-informed MRD test = built “from your tumor up,” customized to your cancer, mainly used to look for minimal residual disease and recurrence.
- Blood-based MRD test = uses a standard panel to look for cancer-specific changes to the DNA in blood, without first studying your tumor.
Your oncology team can explain which test they are using, why it was chosen, and how to interpret the results in your specific situation.
Can MRD testing reduce “scanxiety” or worry about recurrence?
Many people with lung cancer say MRD testing provides another layer of information between scans, which can offer peace of mind when results are negative. For others, an early positive result may feel stressful but also allows more time to act and plan next steps with their care team. It is important to talk with your team about how often to test and how you prefer to receive results so that the information supports your emotional well‑being as well as your care.
Are MRD tests available for all types and stages of lung cancer?
Most current use and research focus on non‑small cell lung cancer (NSCLC), especially in people who have had surgery or other treatment with curative intent. MRD and ctDNA testing are also being studied in more advanced lung cancers and in different treatment settings. Availability and insurance coverage can vary, so your oncologist can tell you whether a personalized MRD test is appropriate and accessible for your specific type and stage of lung cancer.
How do I talk to my doctor about MRD testing for lung cancer?
You can start by asking:
- “Is MRD or ctDNA testing available and appropriate for my type and stage of lung cancer?”
- “What would we do differently based on a positive or negative result?”
- “How often would you recommend testing, and for how long?”
Your doctor can explain how MRD testing fits with your current treatment plan, what the latest evidence shows for lung cancer, and how results would actually change your follow‑up or therapy.
Is MRD testing a replacement for regular lung cancer follow‑up care?
No. MRD testing is meant to complement—not replace—your regular follow‑up visits, scans, blood work, and physical exams. It is one more tool your team can use to personalize your lung cancer care and to help you stay as informed and proactive as possible.
How can MRD and ctDNA testing help people with lung cancer specifically?
For lung cancer, MRD and ctDNA testing can help show whether very small amounts of cancer may still be present after treatment, even when scans look clear. This extra layer of information can help your care team better understand your personal risk of the cancer coming back and decide how closely to monitor you and whether additional treatment—such as targeted therapy or immunotherapy—might be helpful.
When is ctDNA‑based MRD testing usually considered in lung cancer?
Doctors best utilize ctDNA‑based MRD testing when obtained at the time of initial diagnosis. This helps determine prognosis, allows them to monitor your response to treatment and check for any remaining cancer cells that are too small to see on imaging. Testing is typically performed at regular intervals during follow‑up visits to look for early signs of recurrence or to track how well systemic treatments (like chemotherapy, targeted therapy, or immunotherapy) are working.
Can MRD/ctDNA testing help decide if I need more treatment after surgery or radiation?
If ctDNA is still detectable after surgical removal of cancer or after you finish treatment, it suggests a higher risk that lung cancer could come back, and your team might discuss additional treatment choices. If ctDNA is not detected, some patients may be followed with surveillance alone or less intensive therapy, although decisions are always individualized and based on your stage, tumor type (including any specific mutations), response to treatment, and overall health.
How does ctDNA/MRD testing fit with scans and other follow‑up tests for lung cancer?
Standard lung cancer follow‑up relies on imaging (such as CT or PET scans), physical exams, and review of symptoms. ctDNA/MRD testing adds another perspective by looking for tumor DNA in the blood, which in some cases may show changes earlier than imaging. Your doctor will interpret ctDNA/MRD results together with your scans, symptoms, and other tests, rather than using them alone to make decisions.
What does a positive ctDNA/MRD result mean for lung cancer?
A positive ctDNA/MRD result means lung cancer DNA was found in your blood and suggests a higher risk that cancer is still present or may return. Your care team may recommend closer monitoring, more frequent imaging, or additional or different treatments to address that risk, depending on your overall situation.
What does a negative ctDNA/MRD result mean for lung cancer?
A negative ctDNA/MRD result means no lung cancer DNA was detected above the test’s limit at that time, which is generally a reassuring sign and is often linked to a lower risk of recurrence. However, it does not guarantee that the cancer will never come back, so regular scans and follow‑up visits are still needed.
Is ctDNA/MRD testing available for all types and stages of lung cancer?
Most ctDNA/MRD experience is currently in non‑small cell lung cancer, especially in early‑stage or locally advanced disease treated with curative intent, though research is expanding into more advanced stages and into small cell lung cancer. Because test availability, indications, and coverage are evolving, your oncologist is the best person to advise whether this type of testing is appropriate and accessible for you.
What does it mean if my MRD result is “below the limit of detection” or the sample is “inadequate”?
Sometimes an MRD report will say that the amount of tumor DNA in your blood is below the test’s “limit of detection.” This means the test could not reliably measure any cancer DNA at or above the level it is designed to detect at that time. In many cases, this is treated similarly to a negative result and can be reassuring, but it does not prove with 100% certainty that there is no cancer anywhere in the body, so your doctor will still recommend routine follow‑up visits, labs, and scans.
In other situations, the report may say the sample was “inadequate” or “insufficient.” This usually means there was not enough usable DNA in the blood tube, the sample was delayed or mishandled in transit, or there was a technical issue in the lab that prevented a reliable result. An inadequate sample does not tell you anything about whether cancer is present or not. In that case, your care team may recommend repeating the blood draw, waiting until a better time (for example, when your blood counts have recovered), or relying on other tests and scans while deciding whether to try MRD testing again.
These FAQs provide general information and are not a substitute for medical advice. Always talk with your oncology team about whether MRD/ctDNA testing makes sense for your type and stage of lung cancer and how results would affect your care.
Online support: Join the conversation on CancerConnect
More Reading
Non-Small Cell Lung Cancer: What You Need to Know about ctDNA Testing
Learn How ctDNA Testing Can Help Inform Management of Lung Cancer
The Importance of NGS-Biomarker Testing in Lung Cancer
Biomarkers: How Your Cancer’s Unique “Fingerprint” Can Guide Treatment
Advances in Genomic Testing- What You Need to Know
What is Precision Cancer Medicine?
FAQs: NGS-Genomic Testing and Cancer Care
Other Resources: Natera
Facing Recurrence Again? How MRD Testing Can Support You Every Step of the Way
Signatera Results Patient Guide
How to Prepare for Your Next MRD Test: Practical Tips and FAQs
This educational resource was made possible by Natera, OmniOncology, and The Personalized Medicine Foundation.
References:
Li W, Zhang Y, Chen H, et al. Clinical application of minimal residual disease detection by circulating tumor DNA in non–small cell lung cancer. Cancer Med. 2025;14(8):e12345.
Sun L, Wang J, Zhou Q, et al. Minimal residual disease in non‑metastatic non–small cell lung cancer: current evidence and future directions. npj Precis Oncol. 2025;9(1):45.
Li J, Tang Y, Liu X, et al. ctDNA‑based minimal residual disease in non–small cell lung cancer. Thorac Cancer. 2023;14(7):1023‑1034.
Zhang P, Liu Y, Huang J, et al. Personalized, tumor‑informed, circulating tumor DNA assay for detecting minimal residual disease in non–small cell lung cancer patients receiving curative treatments. Thorac Cancer. 2024;15(13):1095‑1102.
Chen K, Zhao H, Shi Y, et al. ctDNA‑based detection of molecular residual disease in stage I–III non–small cell lung cancer treated with definitive radiotherapy. Front Oncol. 2023;13:1253629.
Zhao J, Xu X, Wang R, et al. Individualized tumor‑informed circulating tumor DNA analysis for postoperative monitoring of non–small cell lung cancer. Cancer Cell. 2023;41(12):2051‑2065.e7.
Zhang Y, Garcia‑Murillas I, Coombes RC. Liquid biopsy for minimal residual disease and monitoring in early‑stage solid tumors. Explor Med. 2025;6:1001349.
